Crossmark

Impact of the addition of bevacizumab, oxaliplatin, or irinotecan to fluoropyrimidin in the first-line treatment of metastatic colorectal cancer in elderly patients

Crossref DOI link: https://doi.org/10.1007/s00384-018-3053-3

Published Online: 2018-04-21

Published Print: 2018-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Landre, Thierry

Maillard, Emilie

Taleb, Chérifa

Ghebriou, Djamel

Guetz, Gaetan Des

Zelek, Laurent

Aparicio, Thomas
License Information

Text and Data Mining valid from 2018-04-21
More Information

Article History

Accepted: 9 April 2018

First Online: 21 April 2018

Compliance with ethical standards

:

: TA has received honoraria from Roche and Sanofi; the other authors declare no conflict of interest.

Document is current

Any future updates will be listed below